WO2015050670A1 - Compositions and mehthods for eye whitening - Google Patents
Compositions and mehthods for eye whitening Download PDFInfo
- Publication number
- WO2015050670A1 WO2015050670A1 PCT/US2014/054288 US2014054288W WO2015050670A1 WO 2015050670 A1 WO2015050670 A1 WO 2015050670A1 US 2014054288 W US2014054288 W US 2014054288W WO 2015050670 A1 WO2015050670 A1 WO 2015050670A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adrenergic receptor
- eye
- receptor agonist
- selective
- volume
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 230000002087 whitening effect Effects 0.000 title abstract description 21
- 239000000048 adrenergic agonist Substances 0.000 claims abstract description 66
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 59
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960003679 brimonidine Drugs 0.000 claims abstract description 46
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002048 guanfacine Drugs 0.000 claims abstract description 22
- VTZPAJGVRWKMAG-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-2,3-dihydro-1h-inden-5-ol Chemical compound C12=CC(O)=CC=C2CCC1CC1=CN=CN1 VTZPAJGVRWKMAG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229950006455 fadolmidine Drugs 0.000 claims abstract description 14
- 230000001603 reducing effect Effects 0.000 claims abstract description 11
- -1 dexmedetomidin Chemical compound 0.000 claims abstract description 9
- 230000001965 increasing effect Effects 0.000 claims description 33
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 31
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 24
- 229960004253 dexmedetomidine Drugs 0.000 claims description 16
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 9
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 241001061127 Thione Species 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 20
- 108020003175 receptors Proteins 0.000 abstract description 20
- 201000005111 ocular hyperemia Diseases 0.000 abstract description 5
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract 2
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- 206010020565 Hyperaemia Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 210000003786 sclera Anatomy 0.000 description 7
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 6
- 210000002565 arteriole Anatomy 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 210000004088 microvessel Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000001272 nitrous oxide Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- UYZFAUAYFLEHRC-LURJTMIESA-N L-NIO Chemical compound CC(N)=NCCC[C@H](N)C(O)=O UYZFAUAYFLEHRC-LURJTMIESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ONYFNWIHJBLQKE-ZETCQYMHSA-N N(6)-acetimidoyl-L-lysine Chemical compound CC(=N)NCCCC[C@H](N)C(O)=O ONYFNWIHJBLQKE-ZETCQYMHSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UYZFAUAYFLEHRC-UHFFFAOYSA-N NG-iminoethyl-L-ornithine Natural products CC(N)=NCCCC(N)C(O)=O UYZFAUAYFLEHRC-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 239000002568 adrenergic antihypertensivea Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229940006072 bimatoprost ophthalmic solution Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- ACYGVAVUNGWGBY-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-2-amine Chemical compound N1CCN=C1NC1=CN=C(C=CC=C2)C2=N1 ACYGVAVUNGWGBY-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- VWUPQQFMCOQIEJ-UHFFFAOYSA-M potassium;hydrogen carbonate;hydrate Chemical compound O.[K+].OC([O-])=O VWUPQQFMCOQIEJ-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
Definitions
- the invention is directed to compositions and methods for eye whitening.
- Adrenergic receptors mediate physiological responses to the catecholamines, norepinephrine and epinephrine, and are members of the superfamily of G protein-coupled receptors having seven transmembrane domains.
- a-adrenergic receptors mediate excitatory and inhibitory functions: a- 3 adrenergic receptors are typically excitatory post-synaptic receptors which generally mediate responses in an effector organ, while a-2 adrenergic receptors are located postsynaptieally as weli as presynapticaliy, where they inhibit release of neurotransmitters.
- the a-adrenergic receptors also mediate vascular constriction.
- a-2 adrenergic receptors are presently classified into three subtypes based on their pharmacological and moiecular characterization: -2A/D (a-2A in human and a ⁇ 2D in rat); a- 2B; and a-2C (Bylimd et aL Pharmacol. Rev. 46:121-136 (1994); and Hein and obilka, Neuropharmacol. 34:357-366 (1995)).
- the a ⁇ 2A, a-2B, and -2C subtypes appear to regulate arterial and/or venular contraction in some vascular beds, and the -2A and a-2C subtypes also mediate feedback inhibition of norepinephrine release from sympathetic nerve endings.
- a human eye has a lot of a ⁇ 2 adrenergic receptors. Agonists of these receptors may have an effect on an eye's appearance by causing lumen size reduction of a-2 receptor populated arterioies and, particularly, terminal arterioles. This may result in vasoconstriction, and more particularly microvessel lumen size reduction, which in turn may increase the per unit surface area degree of microvessel constriction, and therefore, improve cosmetic appearance of eyes.
- Whiter eyes are traditionally a societal symbol of natural healthy eyes, and excellent overall hygiene and health.
- While some compounds may be agonists of both a-1 and a-2 receptors, there are many compounds which have selective a-2 agonist activity, meaning, that they preferentially bind to a-2 adrenergic receptors. They include brimonidine (which has been used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension), guanfacine (which has been used to control high blood pressure), fadolmidine (which has been used for spinal analgesia), dexmedetomidine (which has been used as a sedative, analgesic, sympatholytic and anxiolytic), and methyl dopa (which has been used as a centrally acting adrenergic antihypertensive).
- brimonidine which has been used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension
- guanfacine which has been used to control high blood pressure
- a-2 adrenergic receptor agonists when used at conventional doses of 0.1% or higher, are associated with a number of undesirable side effects, such as rebound hyperemia. These effects may be associated with a "cross-over" stimulation of a-1 adrenergic receptors, as a-2 selectivity is a ratio of a-2 /a-1 receptor activity.
- the present invention provides compositions and methods for achieving cosmetic eye whitening which utilize low concentrations of selective a-2 adrenergic receptor agonists.
- the selective a ⁇ 2 adrenergic receptor agonists have binding affinities (K ⁇ ) for a-2 over a-1 receptors of 100: 1 or greater.
- the selective a-2 adrenergic receptor agonists have K; for a-2 over a-1 receptors of 300: 1 or greater, more preferably 500: 1 or greater, more preferably 700:1 or greater, even more preferably 1000: 1 or greater, and most preferably, 1500: 1 or greater.
- concentrations of the selective a-2 adrenergic receptor agonists are from about 0.0001% to about 0,06%: more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0.01 % to about 0.025%; and even more preferably, from about 0.01 % to about 0.02% weight by volume of the composition.
- the selective a-2 adrenergic receptor agonist is selected from the group consisting of, brimonidine, alpha methyi dopa, guanfacine, fadolmidine, dexmedetomidine. (+)-(S)-4-[l-(2,3-dimethyi-pheny3)-ethy!3-l,3-dihydro- imidazole-2-thione, l-[(imidazo3idin-2-yl)imino]indazo!e, and mixtures of these compounds.
- compositions and methods of the invention may be used to whiten healthy eyes and/or to reduce hyperemia in an eye which is due to a disease or a condition.
- the reduction in redness and additional increase in whiteness can be measured on one of the following scales, such as the cSVionnies/Chapman-Davies scale (MC-D); the Institute for Eye Research scale (3ER, previously known as CCLRU scale); the Efron scale; and a validated bulbar redness scale (VBR) developed at the Centre for Contact Lens Research. (The Use of Fractal Analysis and Photometry to Estimate the Accuracy of Bulbar Redness Grading Scales, Marc M. Schulze et al, Investigative Ophthalmology and Visual Science, 2008; 49:1398-1406).
- the invention also describes a modified scale that can more accurately measure the reduction in redness and the additional increase in whiteness.
- the invention is further directed to methods of increasing the whiteness of an eye, decreasing redness of an eye or decreasing redness of an eye while simultaneously increasing whiteness of the eye.
- the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective ⁇ -2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over ot-1 adrenergic receptors, or a pharmaeeutically acceptabie salt thereof; or preferably for subtypes a, b or both.
- J 171 in another embodiment is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist, having a binding affinity of 500 fold or greater for a ⁇ 2 over a- 1 adrenergic receptor.
- the invention is directed to a method of increasing whiteness of an eye comprising adm inistering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist selected from the group consisting of, brimonidlne, alpha methyl dopa, guanfacine, fadoimidine, dexmedetomidme, (+) ⁇ (S) ⁇ 4 ⁇ [l -(2,3 ⁇ dimethyi- phenyl)-ethyl]- 1 ,3-dihydro ⁇ imidazole-2-thione, 1 ⁇ [(imidazolidin-2 ⁇ yi)imino5indazoie, and mixtures of these compounds,
- the inventio is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist present at a concentration from about 0.001 % to about 0.06% weight by volume.
- the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising dexmedetomidine at a concentration from about 0.01% to about 0.060% weight by volume.
- the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising guanfacine at a concentration from about 0.01% to about 0.028% weight by volume.
- the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
- the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising:
- a selective -2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof;
- the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
- the inventio is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 500 fold or greater for a-2 over a-1 adrenergic receptor.
- the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist selected from the group consisting of, brimonidine, alpha .methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+) ⁇ (S) ⁇ 4-[l -(2,3 ⁇ dimethyl- phenyl)-ethyl] ⁇ l .3-dihydro-imidazole-2-lhione, 1 -[(imidazolidi.n-2 ⁇ yl)imino]indazoie, and mixtures of these compounds.
- a selective a-2 adrenergic receptor agonist selected from the group consisting of, brimonidine, alpha .methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+) ⁇ (S) ⁇ 4-[l
- the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective ⁇ -2 adrenergic .receptor agonist present at a concentration from about 0,001% to about 0.06% weight by volume.
- the invention in another embodiment is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising dexmedetomidme at a concentration from about 0,01% to about 0,060% weight by volume, ⁇ 031]
- the invention in another embodimen t is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising guanfacine at a concentration from about 0,01% to about 0.028% ⁇ weight by volume.
- the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
- the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising: ⁇ 034] a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof; and
- the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
- the invention is directed to a method of reducing redness of a eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 500 fold or greater for a-2 over a ⁇ l adrenergic receptor.
- the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering , to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadoimidme, dexmedetomidine, (+)-(S)-4-[ l -(2,3-diniethyi-phenyl)-ethyl]-l,3-dihydro-imidazole-2-thione, l -[(imidazolidin-2-yl)imino]indazo ⁇ e, and mixtures of these compounds.
- a selective a-2 adrenergic receptor selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadoimidme, dexmedetomidine, (+)-(S)-4-[ l -(
- the invention is directed to a method of reducing redness of an eye while sim ultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor present at a concentration from about 0,001 % to about 0.06% weight by volume.
- the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor present at a concentration from about 0.001% to about 0.06% weight by volume using 2
- hydroxypropyl beta cyciodextrin from about 1% to about 12.5% and more preferably about 5.5% for additional redness reducing and whitening effect.
- Figure 1 is a graphical representation of the effects of activating a-i adrenergic receptors
- Figure 2 is a graphical representation of the effects of preferentially activating -2 adrenergic receptors
- Figure 3 is a visual representation of three different shades of whiteness
- Figure 4A is a photograph of an eye of a patient with hyperemia
- Figures 4B-4D are photographs of eyes of healthy individuals
- Figure 5 is a visual representation of the "redness" scale of the invention.
- Figure 6 A i s a photograph of an eye of subject prior to administration of 0.025% brimonidine
- Figure 6B is a photograph of the same eye as in Figure 6A after administration of 0.025% brimonidine;
- Figure 7 is a photograph of an eye of a child patient after administration of 0.025% brimonidine
- Figure 8 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the left eye the right eye is control;
- Figure 9 is a photograph of eyes of a subject, 0.025% brimonidine was administered into both eyes;
- Figure 10 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the right eye; the left eye is control;
- Figure 1 1 A Is a baseline photograph of eyes of a subject prior to administration of 0.025% brimonidine into the right eye;
- Figure 1 I B is a photograph of eyes of the same subject as in Figure 1 1A; 0.025% brimonidine was administered into the right eye; the left eye is control;
- Figure 12 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the right eye; the left eye is control;
- Figure 13 is a photograph of eyes of a subject prior to administration of 0.025% brimonidine into the right eye;
- Figure 14A is a photograph of the right eye of the same subject as in Figure 13; after 0.025% brimonidine was administered into the right eye; and
- Figure 14B is a photograph of the left eye of the same subject as in Figure 13; no brimonidine was administered into the left eye.
- a-2 adrenergic receptor agonists or "a-2 agonists” encompasses all a-2 adrenergic receptor agonists which have a binding affinity of 100 fold or greater for a- 2 over a-1 adrenergic receptors.
- low concentrations refers to concentrations from about 0.0001% to about 0.06%; more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0,01% to about 0.025%; and even more preferably, from about 0.01% to about 0.02% weight by volume of the composition.
- brimonidine encompasses, without limitation, brimonidine salts and other derivatives, and specifically includes, but is not limited to, brimonidine tartrate, 5-bromo-6 ⁇ (2-imidazolin-2-ylamino)quinoxaline D-tartrate, AlphaganTM, and UK14304.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a corabination of the specified ingredients in the specified amounts.
- Embodiments of the Invention [065] It was surprisingly and unexpectedly found that selective alpha-2 (a-2) adrenergic receptor agonists (which are interchangeably referred to as "a-2 agonists" throughout the application) at sufficiently low concentrations allow significant improvement in tissue hemodynamics and can be used for cosmetic whitening of eyes with reduced or eliminated side effects.
- a-2 agonists which are interchangeably referred to as "a-2 agonists” throughout the application
- the invention provides compositions and methods to increase whiteness of an eye.
- the invention provides methods and compositions for achieving eye whitening in healthy eyes, above and beyond reductio of hyperemia due to a disease or a condition.
- the presently claimed methods and compositions can increase whiteness of an eye several shades beyond the baseline of a particular eye. This increase in whiteness may be important for cosmetic or other reasons.
- a normal healthy eye has a certain baseline level of whiteness, which slightly varies from person to person.
- the reduced whiteness of the sclera is often viewed as cosmetically less desirable, and may be an indicator of fatigue, lack of sleep, lack of sobriety, drug use, emotional lability, and overall poor health.
- Whiter sclera is often viewed as more cosmetically desirable, associated with improved hygiene and/or health, and a cleaner, healthier lifestyle.
- the present invention may accomplish this additional whitening through microvascular vasoconstriction of the vessels and, particularly, microvessels of the white layer of the eye (i.e., the sclera).
- compositions and methods of the present invention may affect vasoconstriction of overlying episcleral and/or conjunctival tissue microvessels which may also be involved in the whitening of an eye.
- selective a-2 Adrenergic Receptor Agonists suitable for the Purposes of the Invention [069] in some embodiments of the invention, selective -2 adrenergic receptor agonists have binding affinities ( ⁇ ) for a-2 over a-1 receptors of 100: 1 or greater, In preferred embodiments of the invention, selective a-2 adrenergic receptor agonists have K; for a-2 over a-1 receptors of 300:1 or greater, more preferably 500: 1 or greater, more preferably 700: 1 or greater, even more preferably 1000: 1 or greater, and most preferably, 1500:1 or greater. Generally, a selective a-2 adrenergic receptor agonist which has K, for a-2 over a-1 receptors greater than that of oxymetazoline should be suitable for the purposes of the invention.
- potency, activity or EC5 at an a ⁇ 2A receptor can be determined by assaying for inhibition of adenylate cyclase activity.
- inhibition of adenylate cyclase activity can be assayed, without limitation, in PC 12 cells stably expressing an a ⁇ 2A receptor such as a human a-2A receptor.
- potency, activity or EC50 at an a-lA receptor can be : determined by assaying for intracellular calcium. Intracellular calcium can be assayed, without limitation, in HEK293 cells stably expressing an a-1 A receptor, such as a bovine a-1 A receptor.
- the particularly preferred adrenergic receptor agonists for the purposes of the present invention have higher selectivity for a-2B and/or a ⁇ 2C receptors, as compared to a-2A receptors.
- concentrations of selective a-2 adrenergic receptor agonists are from about 0,0001% to about 0.06%; more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0.01 % to about 0.025%; and even more preferably, from about 0.01?/ ⁇ to about 0.02% weight by volume of the composition.
- Any selective a-2 adrenergic receptor agonist may be suitable for the purposes of the present invention.
- the selective a-2 adrenergic receptor agonist is selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetornidme, (+)-(S)-4-[l -(2,3-dimethyl-phenyl)-ethy ⁇ ]-l ,3-dihydro- imidazoie-2-thione, ] -[(imidazoiidin-2-yl)imino]indazole, and mixtures of these compounds, [074] Compositions and methods of the inventions encompass all isomeric forms of the described a-2 adrenergic receptor agonists, their racemic mixtures, enol forms, solvated and unsoivated forms, analogs, prodrugs, derivatives, including but not limited to esters and ethers, and pharmaceutically acceptable salts, including acid addition salts.
- suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, furmaric, succinic, ascorbic, maleic, methanesulfonic, tartaric, and other mineral carboxylic acids well known to those in the art.
- the salts may be prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
- the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous hydroxide potassium carbonate, ammonia, and sodium bicarbonate.
- the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid salts are equivalent to their respective free base forms for purposes of the invention. (See, for example S. M. Berge, et a!., "Pharmaceutical Salts,” I Pharm. Sci., 66: 1 -19 (1977) which is incorporated herein by reference).
- a selective a-2 adrenergic receptor agonist functions as a highly selective a-2 agonist, it may be used for the purposes of the present inven tion.
- a particular a-2 adrenergic receptor agonist one may take into account various considerations including blood brain permeability and any possible side effects and other systemic reactions.
- the selective -2 adrenergic receptor agonist is brimonidine or its salt, in a more preferred embodiment, the selective a-2 adrenergic receptor agonist is the tartrate salt of brimonidine.
- the selective a-2 adrenergic receptor agonist is dexmedetomidine or its salt.
- the selective a-2 adrenergic receptor agonist is guanfacine or its salt.
- the selective a-2 adrenergic receptor agonist is fadolmidine or its salt.
- the invention provides a composition comprising a low dose of a selective a-2 adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in increasing whiteness of an eye.
- the selectiv a-2 adrenergic receptor agonist is present at a concentration below about 0,06% weight by volume, and more preferably, from about 0.001% to about 0,06% weight by volume,
- the concentration of the selective a-2 adrenergic receptor agonist is preferably below the conceniTation at which a-1 adrenergic receptors are sufficiently activated to cause adverse ischemic vasoconstrictive consequences.
- the selective a-2 adrenergic receptor agonist is selected from the group consisting of lofexidine, apraclonidine, mi ' vazerol, clonidme, brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+)-fS)-4-[l- ⁇ 2,3-dimethyl- pheny -ethylj-l.S-dihydro-imidazole ⁇ -thione, l-[(imidazolidln-2-y3)imino]indazo!e, and mixtures of these compounds.
- the composition comprises brimonidine at a concentration from about 0.01% to about 0.025% weight by volume.
- the composition comprises dexniedetomidine at a concentration from about 0.01% to about 0,060% weight by volume.
- the composition comprises guanfacine at a concentration from about 0.01% to about 0.028% weight by volume.
- the composition comprises fadoimidine at a concentration from about 0.01 % to about 0.025% weight by volume.
- a pH of the composition comprising the selective a-2 adrenergic receptor agonist is from about 5.5 to about 6.5.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of brimonidine, wherein brimonidine concentration is from about 0,01% to about 0.025% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of dexmedetomidine, wherein dexniedetomidine concentration is from about 0.01% to about. 0.060% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of guanfacine, wherein guanfacine concentration is from about 0.01% to about 0.028% weight by volume, wherein pH of said composition is from about 5.5 to about 7.5.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of fadoimidine, wherein fadolmidine concentration is from about 0.01 % to about 0.025% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.025% weight by volume of brimonidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01% to about 0,060% weight by volume of dexmedetomidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.028% weigh t by volume of guanfacine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
- the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.025% weight by volume of fadoimidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
- the compositions of the present invention are preferably formulated for a mammal, and more preferably, for a human.
- a pH of the compositions of the present invention is less than about 8,0, preferably, from about. 5.5 to about 8.0, more preferably from about 6.0 to about 8.0.
- compositions of. the present invention further include potassium (i.e., K ⁇ ).
- potassium i.e., K ⁇
- the term “potassium” includes, but is not limited to, potassium salt.
- potassium is in the form of potassium chloride (KCI) and its concentration is from about 0.2% to about 0.9% weight by volume.
- compositions of the present invention further include calcium (i.e., Ca 2+ ),
- calcium i.e., Ca 2+
- the term "calcium” includes, but is not limited to, calcium salt.
- calcium is calcium chloride (CaCfe).
- the selective a-2 adrenergic receptor agonist has KCI in a concentration range of 0. 1 % - 0.8% weight by volume, preferably 0.25% weight, by volume.
- the higher concentration of KCI may contribute to a more prolonged duration of action of compositions of the invention.
- compositions of the invention may have pH of above 7.0 and KCI of 0.1% - 0.8% weight by volume.
- compositions of the Invention may have a pH of above 7.0 and KCI of 0.1 % ⁇ 0.8% and CaCl 2 above 0.01 % weight by volume.
- compositions of the invention also comprise a solubility stabilizer which preferably contains an anionic component, such as peroxide class preservatives.
- the solubility stabilizer allows one to achieve greater penetration of lipophilic membranes.
- the solubility stabilizer comprises a stabilized oxych!oro complex, chlorite, and sodium perborate.
- compositions of the present invention comprise nitrous oxide inhibitors
- the nitrous oxide inhibitors are selected from the group consisting of L-NA E (L-N G -Nitroarginme methyl ester), L-NIL (N6-(I -Imlnoethyl) ⁇ L-jysine dihydrochloride), L-NIO (N5-(l -iminoethyl)-L-omithme dihydrochloride), and L-canavine,. or combinations thereof.
- concentration of the nitrous oxide inhibitors is from about 0.005% to about 0.5% weight by volume.
- compositions are delivered as ophthalmic solutions into the eyes.
- topical compositions which include, but are not limited to, gels and creams. They may also include additional non-therapeutic components, which include, but are not limited to, preservatives, delivery vehicles, tonicity adjusters, buffers, pH adjusters, antioxidants, and water.
- Preservatives include, but are not limited to, benzalkonium chloride, chiorobutanoi, thimerosal, pheny!mercuric acetate, or phenylmercuric nitrate.
- Delivery vehicles include, but. are not limited to, polyvinyl alcohol, povidone, hydroxypropyi methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water, it is also possible to use a physiological saline solution as a major vehicle.
- Tonicit adjusters include, but are not limited to, a salt such as sodium chloride, potassium chloride, mannitol or glycerin, or another pharmaceutically or opbthaimicaily acceptable tonicity adjuster.
- Buffers and pH adjusters include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. It is understood that acids or bases can be used to adjust the pH of the composition as needed.
- Antioxidants include, but are not limited to, sodium metabi sulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxyioluene.
- Antioxidants include, but are not limited to, sodium metabi sulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxyioluene.
- To make the iopieal compositions of the present invention one can simply dilute, using methods known in the art, more concentrated solutions of selective a-2 agonists. The precise method of carrying out the dilutions is not critical. Any commonly used diluents, including preservatives described above in the application, suitable for topical solutions can be used.
- compositions of the invention may be formulated and delivered as intravenous, oral, aerosolized, and nebulized compositions.
- compositions of the present invention are concentration- dependent.
- a skilled artisan would have to take into account kinetics and absorption characteristics of the particular selective a-2 adrenergic receptor agonist.
- the dosage may be dependent on the route of admi istration.
- the dosages may also dependent on the degree of whitening desired by a patient.
- FIG. 1 is a graphical representation of the effects of activating a-1 adrenergic receptors.
- administering a-1 adrenergic receptor agonists leads to constriction of the proximal arteriole (on the left side of FIG. .1) which in turn decreases the flow of blood through the capillaries and causes ischemia for the tissues downstream of the constricted arteriole.
- FIG. 2 is a graphical representation of the effects of preferentially activating a-2 adrenergic receptors.
- administering a-2 adrenergic receptor agonists leads to constriction of the pre-capillary/ierminal arteriole (i.e. smaller blood vessel) (on the left side of FIG. 1) and constriction of the venule (on the right side of FIG. 2).
- Ischemia is decreased, as compared to stimulating a-1 adrenergic receptors, because the arteriole is open and some oxygen is available to surrounding tissues by means of the through-flow vessels that connect the arterioles and the venules.
- FIG. 3 is a visual representation of three different shades of whiteness.
- the human eye has a limit to its ability to discriminate shades of whiteness change.
- the central square is set to RGB (255 255 255).
- the RGB color model is an additive color model in which red, green, and blue light are added together in various ways to reproduce a broad array of colors.
- a color in the RGB color model is described by indicating how much of each of the red, green, and blue is included.
- the color is expressed as an RGB triplet (rgb), each component of which can vary from zero to a defined maximum value. If all the components are at zero, the result is black; if all are at maximum, the result is the fully saturated white, RGB (255 255 255) represents the fully saturated white.
- the whiteness has been reduced by 5, based on a 1 to 100 blackness scale, where the background is 100.
- the whiteness has been reduced by 15.
- the shade differential resulting from reduction by 5 is just above the threshold increment of difference in whitening detectable by most humans with normal healthy eyes.
- FIG. 4a is a photograph of an eye of a patient with hyperemia.
- Hyperemia dilation of vessels of the conjunctiva, and less frequently underlying episclera and/or sclera
- FIG. 5 illustrates the new scale according to the present invention which allows one to quantify sclera color beyond removal of hyperemia
- FIG. 9A is a photograph of the eye prior to administration of 0.025% brimonidine.
- FIG. 9B is a photograph of the same eye after administration of 0.025% brimonidine.
- FIG. 10 is a photograph of the eye after administration of 0.025% brimonidine.
- FIG. 8 is a photograph of subject #1, the drug was administered into the left eye; the right eye is control;
- FIG. 9 is a photograph of subject #2, the drug was administered into both eyes;
- FIG. 10 is a photograph of subject #3, the drug was administered into the right eye; the left eye is control;
- FIG. 1 1 A is a photograph of subject #4, the photograph is the baseline and was taken prior to administration of the drug;
- FIG. 1 IB is a photograph of subject #4, the drug was administered into the right eye; the left eye is control; and
- FIG. 12 is photograph of subject #5, the drug was administered into the righ eye; the left eye is control.
- Example 4-Effeet ofBrimonidine on Increasing of Cosmetic Whiteness of an Eye A 40-year-old woman with healthy eyes was administered 1 gtt (dro per minute) of 0.025% brirrsomdine into the right eye for three minutes.
- FIG. 13 is a photograph of both eyes of the woman before the drug was administered.
- FIG. 14A is a ciose-up photograph of the right eye and
- FIG. 14B is a close-up photograph of the left eye.
- TMD denotes to be determined.
- Redness reduction is on a scale from 0.00 to 4.00 with 0.00 denoting the greatest redness reduction and 4.00 denoting no redness reduction.
- Whitening is on a scale from 0.00 to 4.00 with 0.00 denoting pearly white, glistening color and 4.00 denoting no whitening effect.
- the comparable baseline redness (i.e. before application of an a-2 agonist) for general is 2+ on a 4.0 scale and drug induced redness score is 3+ on a 4.0 scale with 0.0 denoting no redness and 4.0 denoting the most redness.
Abstract
The invention provides compositions and methods tor whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective alpha-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidin, guanfacine or fadolmidine. In some embodiments of the invention, the selective alpha-2 adrenergic receptor agonists have binding affinities (Ki) for alpha-2 over alpha-1 receptors of 100:1 or greater.
Description
COMPOSITIONS AND METHODS FOR EYE WHITENING
Field of the Invention
[001] The invention is directed to compositions and methods for eye whitening.
Background of the Invention
[002] Adrenergic receptors mediate physiological responses to the catecholamines, norepinephrine and epinephrine, and are members of the superfamily of G protein-coupled receptors having seven transmembrane domains.
[003] These receptors, which are divided pharmacologically into a-1, a-2 and β-adrenergic receptor types, are involved in diverse physiological functions including functions of the cardiovascular and central nervous systems. The a-adrenergic receptors mediate excitatory and inhibitory functions: a- 3 adrenergic receptors are typically excitatory post-synaptic receptors which generally mediate responses in an effector organ, while a-2 adrenergic receptors are located postsynaptieally as weli as presynapticaliy, where they inhibit release of neurotransmitters. The a-adrenergic receptors also mediate vascular constriction.
{004] a-2 adrenergic receptors are presently classified into three subtypes based on their pharmacological and moiecular characterization: -2A/D (a-2A in human and a~2D in rat); a- 2B; and a-2C (Bylimd et aL Pharmacol. Rev. 46:121-136 (1994); and Hein and obilka, Neuropharmacol. 34:357-366 (1995)). The a~2A, a-2B, and -2C subtypes appear to regulate arterial and/or venular contraction in some vascular beds, and the -2A and a-2C subtypes also mediate feedback inhibition of norepinephrine release from sympathetic nerve endings.
[005] A human eye has a lot of a~2 adrenergic receptors. Agonists of these receptors may have an effect on an eye's appearance by causing lumen size reduction of a-2 receptor populated arterioies and, particularly, terminal arterioles. This may result in vasoconstriction, and more particularly microvessel lumen size reduction, which in turn may increase the per unit surface area degree of microvessel constriction, and therefore, improve cosmetic
appearance of eyes. Whiter eyes are traditionally a societal symbol of natural healthy eyes, and excellent overall hygiene and health.
[006] While some compounds may be agonists of both a-1 and a-2 receptors, there are many compounds which have selective a-2 agonist activity, meaning, that they preferentially bind to a-2 adrenergic receptors. They include brimonidine (which has been used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension), guanfacine (which has been used to control high blood pressure), fadolmidine (which has been used for spinal analgesia), dexmedetomidine (which has been used as a sedative, analgesic, sympatholytic and anxiolytic), and methyl dopa (which has been used as a centrally acting adrenergic antihypertensive).
[007] However, selective a-2 adrenergic receptor agonists, when used at conventional doses of 0.1% or higher, are associated with a number of undesirable side effects, such as rebound hyperemia. These effects may be associated with a "cross-over" stimulation of a-1 adrenergic receptors, as a-2 selectivity is a ratio of a-2 /a-1 receptor activity.
[008] Thus, there is a need for new compositions and methods that would improve cosmetic appearance of eyes by achieving eye whitening with reduced or eliminated side effects.
Summary of the Invention
[009] The present invention provides compositions and methods for achieving cosmetic eye whitening which utilize low concentrations of selective a-2 adrenergic receptor agonists.
[010] In some embodiments of the invention, the selective a~2 adrenergic receptor agonists have binding affinities (K{) for a-2 over a-1 receptors of 100: 1 or greater. In preferred embodiments of the invention, the selective a-2 adrenergic receptor agonists have K; for a-2 over a-1 receptors of 300: 1 or greater, more preferably 500: 1 or greater, more preferably 700:1 or greater, even more preferably 1000: 1 or greater, and most preferably, 1500: 1 or greater.
[Oil] In preferred embodiments of the invention, concentrations of the selective a-2 adrenergic receptor agonists are from about 0.0001% to about 0,06%: more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0.01 % to about 0.025%; and even more preferably, from about 0.01 % to about 0.02% weight by volume of the composition.
[012] In preferred embodiments of the invention, the selective a-2 adrenergic receptor agonist is selected from the group consisting of, brimonidine, alpha methyi dopa, guanfacine, fadolmidine, dexmedetomidine. (+)-(S)-4-[l-(2,3-dimethyi-pheny3)-ethy!3-l,3-dihydro- imidazole-2-thione, l-[(imidazo3idin-2-yl)imino]indazo!e, and mixtures of these compounds.
[013] The compositions and methods of the invention may be used to whiten healthy eyes and/or to reduce hyperemia in an eye which is due to a disease or a condition.
[014] The reduction in redness and additional increase in whiteness can be measured on one of the following scales, such as the cSVionnies/Chapman-Davies scale (MC-D); the Institute for Eye Research scale (3ER, previously known as CCLRU scale); the Efron scale; and a validated bulbar redness scale (VBR) developed at the Centre for Contact Lens Research. (The Use of Fractal Analysis and Photometry to Estimate the Accuracy of Bulbar Redness Grading Scales, Marc M. Schulze et al, Investigative Ophthalmology and Visual Science, 2008; 49:1398-1406). Alternatively, the invention also describes a modified scale that can more accurately measure the reduction in redness and the additional increase in whiteness.
[015] The invention is further directed to methods of increasing the whiteness of an eye, decreasing redness of an eye or decreasing redness of an eye while simultaneously increasing whiteness of the eye.
[016] In one embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a
selective α-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over ot-1 adrenergic receptors, or a pharmaeeutically acceptabie salt thereof; or preferably for subtypes a, b or both.
J 171 In another embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist, having a binding affinity of 500 fold or greater for a~2 over a- 1 adrenergic receptor.
[018] In another embodiment the invention is directed to a method of increasing whiteness of an eye comprising adm inistering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist selected from the group consisting of, brimonidlne, alpha methyl dopa, guanfacine, fadoimidine, dexmedetomidme, (+)~(S)~4~[l -(2,3~dimethyi- phenyl)-ethyl]- 1 ,3-dihydro~imidazole-2-thione, 1 ~[(imidazolidin-2~yi)imino5indazoie, and mixtures of these compounds,
[0i 9] In another embodiment the inventio is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist present at a concentration from about 0.001 % to about 0.06% weight by volume.
[020] In another embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising dexmedetomidine at a concentration from about 0.01% to about 0.060% weight by volume.
[021] I another embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising guanfacine at a concentration from about 0.01% to about 0.028% weight by volume.
[022] In another embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
[023] in another embodiment the invention is directed to a method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising:
[024] a selective -2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof; and
|025] from about 0.005% to 0.01% weight by volume of calcium chloride.
[026] I n one embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
[027] In another embodiment the inventio is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 500 fold or greater for a-2 over a-1 adrenergic receptor.
[028] In another embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist selected from the group consisting of, brimonidine, alpha .methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+)~(S)~4-[l -(2,3~dimethyl- phenyl)-ethyl]~l .3-dihydro-imidazole-2-lhione, 1 -[(imidazolidi.n-2~yl)imino]indazoie, and mixtures of these compounds.
[029] In another embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising a
selective α-2 adrenergic .receptor agonist present at a concentration from about 0,001% to about 0.06% weight by volume.
[©30] in another embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising dexmedetomidme at a concentration from about 0,01% to about 0,060% weight by volume, {031] In another embodimen t the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising guanfacine at a concentration from about 0,01% to about 0.028%· weight by volume.
[032] In another embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
{033] n another embodiment the invention is directed to a method of decreasing redness of an eye comprising administering to a subject in need thereof a composition comprising: {034] a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof; and
[035] from about 0.005% to 0.01 % weight by volume of calcium chloride.
{036] In one embodiment the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
[037] In another embodiment the invention is directed to a method of reducing redness of a eye while simultaneously increasing whiteness of the eye comprising administering to a
subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 500 fold or greater for a-2 over a~l adrenergic receptor.
[038] In another embodiment the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering, to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadoimidme, dexmedetomidine, (+)-(S)-4-[ l -(2,3-diniethyi-phenyl)-ethyl]-l,3-dihydro-imidazole-2-thione, l -[(imidazolidin-2-yl)imino]indazo{e, and mixtures of these compounds.
[039] In another embodiment the invention is directed to a method of reducing redness of an eye while sim ultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor present at a concentration from about 0,001 % to about 0.06% weight by volume.
[040] In another embodiment the invention is directed to a method of reducing redness of an eye while simultaneously increasing whiteness of the eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor present at a concentration from about 0.001% to about 0.06% weight by volume using 2
hydroxypropyl beta cyciodextrin from about 1% to about 12.5% and more preferably about 5.5% for additional redness reducing and whitening effect.
Brief Description of the Figures
[041 ] The file of this patent contains at least one drawing executed in color. Copies of this patent with, color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.
[042] Figure 1 is a graphical representation of the effects of activating a-i adrenergic receptors;
[043] Figure 2 is a graphical representation of the effects of preferentially activating -2 adrenergic receptors;
[044] Figure 3 is a visual representation of three different shades of whiteness;
[045] Figure 4A is a photograph of an eye of a patient with hyperemia;
[046] Figures 4B-4D are photographs of eyes of healthy individuals;
[047] Figure 5 is a visual representation of the "redness" scale of the invention;
[048] Figure 6 A i s a photograph of an eye of subject prior to administration of 0.025% brimonidine;
[049] Figure 6B is a photograph of the same eye as in Figure 6A after administration of 0.025% brimonidine;
[050] Figure 7 is a photograph of an eye of a child patient after administration of 0.025% brimonidine;
[051] Figure 8 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the left eye the right eye is control;
[052] Figure 9 is a photograph of eyes of a subject, 0.025% brimonidine was administered into both eyes;
[053] Figure 10 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the right eye; the left eye is control;
[054] Figure 1 1 A Is a baseline photograph of eyes of a subject prior to administration of 0.025% brimonidine into the right eye;
[055] Figure 1 I B is a photograph of eyes of the same subject as in Figure 1 1A; 0.025% brimonidine was administered into the right eye; the left eye is control;
[056] Figure 12 is a photograph of eyes of a subject, 0.025% brimonidine was administered into the right eye; the left eye is control;
[057] Figure 13 is a photograph of eyes of a subject prior to administration of 0.025% brimonidine into the right eye;
[058] Figure 14A is a photograph of the right eye of the same subject as in Figure 13; after 0.025% brimonidine was administered into the right eye; and
[059] Figure 14B is a photograph of the left eye of the same subject as in Figure 13; no brimonidine was administered into the left eye.
Detailed Description of the Invention
Definitions
[060) For purposes of the present in vention, the terms beiow are defined as follows.
[061] The term "selective a-2 adrenergic receptor agonists" or "a-2 agonists" encompasses all a-2 adrenergic receptor agonists which have a binding affinity of 100 fold or greater for a- 2 over a-1 adrenergic receptors.
[062] The term "low concentrations" refers to concentrations from about 0.0001% to about 0.06%; more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0,01% to about 0.025%; and even more preferably, from about 0.01% to about 0.02% weight by volume of the composition.
[063] The term "brimonidine" encompasses, without limitation, brimonidine salts and other derivatives, and specifically includes, but is not limited to, brimonidine tartrate, 5-bromo-6~ (2-imidazolin-2-ylamino)quinoxaline D-tartrate, Alphagan™, and UK14304.
[064] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a corabination of the specified ingredients in the specified amounts.
Embodiments of the Invention
[065] It was surprisingly and unexpectedly found that selective alpha-2 (a-2) adrenergic receptor agonists (which are interchangeably referred to as "a-2 agonists" throughout the application) at sufficiently low concentrations allow significant improvement in tissue hemodynamics and can be used for cosmetic whitening of eyes with reduced or eliminated side effects.
[066] Thus, in one aspect, the invention provides compositions and methods to increase whiteness of an eye. In one embodiment, the invention provides methods and compositions for achieving eye whitening in healthy eyes, above and beyond reductio of hyperemia due to a disease or a condition.
[067] The presently claimed methods and compositions can increase whiteness of an eye several shades beyond the baseline of a particular eye. This increase in whiteness may be important for cosmetic or other reasons. A normal healthy eye has a certain baseline level of whiteness, which slightly varies from person to person. The reduced whiteness of the sclera is often viewed as cosmetically less desirable, and may be an indicator of fatigue, lack of sleep, lack of sobriety, drug use, emotional lability, and overall poor health. Whiter sclera is often viewed as more cosmetically desirable, associated with improved hygiene and/or health, and a cleaner, healthier lifestyle.
[068] Not wishing to be bound to a specific theory, the present invention may accomplish this additional whitening through microvascular vasoconstriction of the vessels and, particularly, microvessels of the white layer of the eye (i.e., the sclera). In addition, compositions and methods of the present invention may affect vasoconstriction of overlying episcleral and/or conjunctival tissue microvessels which may also be involved in the whitening of an eye. This effect is believed to be similar to teeth whitening, where grading scale quantification includes improvement relative to an estimated baseline, where whitening beyond baseline is referred to as "bleaching."
Selective a-2 Adrenergic Receptor Agonists Suitable for the Purposes of the Invention [069] in some embodiments of the invention, selective -2 adrenergic receptor agonists have binding affinities (Κ·) for a-2 over a-1 receptors of 100: 1 or greater, In preferred embodiments of the invention, selective a-2 adrenergic receptor agonists have K; for a-2 over a-1 receptors of 300:1 or greater, more preferably 500: 1 or greater, more preferably 700: 1 or greater, even more preferably 1000: 1 or greater, and most preferably, 1500:1 or greater. Generally, a selective a-2 adrenergic receptor agonist which has K, for a-2 over a-1 receptors greater than that of oxymetazoline should be suitable for the purposes of the invention.
[070] It is well within a skill in the art to design an assay to determine α-2/α-Ι functional selectivity. As non-limiting examples, potency, activity or EC5 at an a~2A receptor can be determined by assaying for inhibition of adenylate cyclase activity. Furthermore, inhibition of adenylate cyclase activity can be assayed, without limitation, in PC 12 cells stably expressing an a~2A receptor such as a human a-2A receptor. As further non-limiting examples, potency, activity or EC50 at an a-lA receptor can be: determined by assaying for intracellular calcium. Intracellular calcium can be assayed, without limitation, in HEK293 cells stably expressing an a-1 A receptor, such as a bovine a-1 A receptor.
[071] Not desiring to be bound by any specific theory or mechanism, it is believed that the particularly preferred adrenergic receptor agonists for the purposes of the present invention have higher selectivity for a-2B and/or a~2C receptors, as compared to a-2A receptors.
[072] In preferred embodiments of the invention, concentrations of selective a-2 adrenergic receptor agonists are from about 0,0001% to about 0.06%; more preferably, from about 0.001% to about 0.025%; even more preferably, from about 0.01 % to about 0.025%; and even more preferably, from about 0.01?/ό to about 0.02% weight by volume of the composition.
[073] Any selective a-2 adrenergic receptor agonist may be suitable for the purposes of the present invention. In one embodiment, the selective a-2 adrenergic receptor agonist is selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetornidme, (+)-(S)-4-[l -(2,3-dimethyl-phenyl)-ethy{]-l ,3-dihydro- imidazoie-2-thione, ] -[(imidazoiidin-2-yl)imino]indazole, and mixtures of these compounds, [074] Compositions and methods of the inventions encompass all isomeric forms of the described a-2 adrenergic receptor agonists, their racemic mixtures, enol forms, solvated and unsoivated forms, analogs, prodrugs, derivatives, including but not limited to esters and ethers, and pharmaceutically acceptable salts, including acid addition salts. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, furmaric, succinic, ascorbic, maleic, methanesulfonic, tartaric, and other mineral carboxylic acids well known to those in the art. The salts may be prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous hydroxide potassium carbonate, ammonia, and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid salts are equivalent to their respective free base forms for purposes of the invention. (See, for example S. M. Berge, et a!., "Pharmaceutical Salts," I Pharm. Sci., 66: 1 -19 (1977) which is incorporated herein by reference).
[075] As long as a particular isomer, salt, analog, prodrug or other derivative of a selective a-2 adrenergic receptor agonist functions as a highly selective a-2 agonist, it may be used for the purposes of the present inven tion.
[076] When choosing a particular a-2 adrenergic receptor agonist, one may take into account various considerations including blood brain permeability and any possible side effects and other systemic reactions.
[077] In preferred embodiments of the invention, the selective -2 adrenergic receptor agonist is brimonidine or its salt, in a more preferred embodiment, the selective a-2 adrenergic receptor agonist is the tartrate salt of brimonidine.
[078] in other preferred embodiments of the invention, the selective a-2 adrenergic receptor agonist is dexmedetomidine or its salt.
[079] In other preferred embodiments of the invention, the selective a-2 adrenergic receptor agonist is guanfacine or its salt.
[080] In other preferred embodiments of the invention, the selective a-2 adrenergic receptor agonist is fadolmidine or its salt.
Compositions and Methods of the Invention
[081] In one embodiment, the invention provides a composition comprising a low dose of a selective a-2 adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in increasing whiteness of an eye.
[082] In a preferred embodiment, the selectiv a-2 adrenergic receptor agonist is present at a concentration below about 0,06% weight by volume, and more preferably, from about 0.001% to about 0,06% weight by volume,
[083] The concentration of the selective a-2 adrenergic receptor agonist is preferably below the conceniTation at which a-1 adrenergic receptors are sufficiently activated to cause adverse ischemic vasoconstrictive consequences.
[084] In one embodiment, the selective a-2 adrenergic receptor agonist is selected from the group consisting of lofexidine, apraclonidine, mi'vazerol, clonidme, brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+)-fS)-4-[l-{2,3-dimethyl-
pheny -ethylj-l.S-dihydro-imidazole^-thione, l-[(imidazolidln-2-y3)imino]indazo!e, and mixtures of these compounds.
[085] In a preferred einbodiment, the composition comprises brimonidine at a concentration from about 0.01% to about 0.025% weight by volume.
[086] In another preferred embodiment, the composition comprises dexniedetomidine at a concentration from about 0.01% to about 0,060% weight by volume.
[087] In another preferred embodiment, the composition comprises guanfacine at a concentration from about 0.01% to about 0.028% weight by volume.
[088] In another preferred embodiment, the composition comprises fadoimidine at a concentration from about 0.01 % to about 0.025% weight by volume.
[089] in a more preferred embodiment, a pH of the composition comprising the selective a-2 adrenergic receptor agonist is from about 5.5 to about 6.5.
[090] In one embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of brimonidine, wherein brimonidine concentration is from about 0,01% to about 0.025% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
[091] In another embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of dexmedetomidine, wherein dexniedetomidine concentration is from about 0.01% to about. 0.060% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
[092] In another embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of guanfacine, wherein guanfacine concentration is from about 0.01% to about 0.028% weight by volume, wherein pH of said composition is from about 5.5 to about 7.5.
[093] ϊη another embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, consisting essentially of fadoimidine, wherein fadolmidine concentration is from about 0.01 % to about 0.025% weight by volume, wherein pH of said composition is from about 5.5 to about 7.0.
[094] in a preferred embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.025% weight by volume of brimonidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
[095] In another preferred embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01% to about 0,060% weight by volume of dexmedetomidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
[096] in another preferred embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.028% weigh t by volume of guanfacine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
[097] In another preferred embodiment, the invention provides an aqueous composition for use in increasing whiteness of an eye, comprising from about 0.01 % to about 0.025% weight by volume of fadoimidine and from about 0.1 to about 0.5% weight by volume of potassium chloride, wherein pH of said composition is from about 7.0 to about 8.0, and wherein said composition is formulated for a topical administration.
[098] The compositions of the present invention are preferably formulated for a mammal, and more preferably, for a human.
[099] In one embodiment, a pH of the compositions of the present invention is less than about 8,0, preferably, from about. 5.5 to about 8.0, more preferably from about 6.0 to about 8.0.
(0100] In another preferred embodiment, the compositions of. the present invention further include potassium (i.e., K÷). The term "potassium" includes, but is not limited to, potassium salt. In a preferred embodiment, potassium is in the form of potassium chloride (KCI) and its concentration is from about 0.2% to about 0.9% weight by volume.
(0101) In another preferred embodiment, the compositions of the present invention further include calcium (i.e., Ca2+), The term "calcium" includes, but is not limited to, calcium salt. Preferably, calcium is calcium chloride (CaCfe).
[0102] In a more preferred embodiment, the selective a-2 adrenergic receptor agonist has KCI in a concentration range of 0. 1 % - 0.8% weight by volume, preferably 0.25% weight, by volume. The higher concentration of KCI may contribute to a more prolonged duration of action of compositions of the invention.
[0103] In a still more preferred embodiment, the compositions of the invention may have pH of above 7.0 and KCI of 0.1% - 0.8% weight by volume.
[0104] In a still more preferred embodiment, the compositions of the Invention may have a pH of above 7.0 and KCI of 0.1 % ~ 0.8% and CaCl2 above 0.01 % weight by volume.
[0105] In another preferred embodiment, the compositions of the invention also comprise a solubility stabilizer which preferably contains an anionic component, such as peroxide class preservatives. The solubility stabilizer allows one to achieve greater penetration of lipophilic membranes. In a preferred embodiment, the solubility stabilizer comprises a stabilized oxych!oro complex, chlorite, and sodium perborate.
[0106] In yet another preferred embodiment, the compositions of the present invention comprise nitrous oxide inhibitors, in a preferred embodiment, the nitrous oxide inhibitors are selected from the group consisting of L-NA E (L-NG-Nitroarginme methyl ester), L-NIL (N6-(I -Imlnoethyl)~L-jysine dihydrochloride), L-NIO (N5-(l -iminoethyl)-L-omithme dihydrochloride), and L-canavine,. or combinations thereof. Preferably, concentration of the nitrous oxide inhibitors is from about 0.005% to about 0.5% weight by volume.
[0107] In one embodiment of the invention, the compositions are delivered as ophthalmic solutions into the eyes. The invention also contemplates topical compositions which include, but are not limited to, gels and creams. They may also include additional non-therapeutic components, which include, but are not limited to, preservatives, delivery vehicles, tonicity adjusters, buffers, pH adjusters, antioxidants, and water.
[0108} Preservatives include, but are not limited to, benzalkonium chloride, chiorobutanoi, thimerosal, pheny!mercuric acetate, or phenylmercuric nitrate.
[0109] Delivery vehicles include, but. are not limited to, polyvinyl alcohol, povidone, hydroxypropyi methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water, it is also possible to use a physiological saline solution as a major vehicle.
[0110] Tonicit adjusters include, but are not limited to, a salt such as sodium chloride, potassium chloride, mannitol or glycerin, or another pharmaceutically or opbthaimicaily acceptable tonicity adjuster.
[0111] Buffers and pH adjusters include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. It is understood that acids or bases can be used to adjust the pH of the composition as needed.
[0112] Antioxidants include, but are not limited to, sodium metabi sulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxyioluene.
[0113] To make the iopieal compositions of the present invention, one can simply dilute, using methods known in the art, more concentrated solutions of selective a-2 agonists. The precise method of carrying out the dilutions is not critical. Any commonly used diluents, including preservatives described above in the application, suitable for topical solutions can be used.
[0114] In other embodiments, the compositions of the invention may be formulated and delivered as intravenous, oral, aerosolized, and nebulized compositions.
Dosages
[0115] Proper dosages of the compositions of the present invention are concentration- dependent. To determine the specific dose for whitening of eyes of a specific person, a skilled artisan would have to take into account kinetics and absorption characteristics of the particular selective a-2 adrenergic receptor agonist. In addition, the dosage may be dependent on the route of admi istration. The dosages may also dependent on the degree of whitening desired by a patient.
[0116] The present invention is more fully demonstrated by reference to the accompanying drawings.
[0117] Figure (FIG) 1 is a graphical representation of the effects of activating a-1 adrenergic receptors. As FIG. 1 demonstrates, administering a-1 adrenergic receptor agonists leads to constriction of the proximal arteriole (on the left side of FIG. .1) which in turn decreases the flow of blood through the capillaries and causes ischemia for the tissues downstream of the constricted arteriole.
[01 18] FIG. 2 is a graphical representation of the effects of preferentially activating a-2 adrenergic receptors, As FIG. 2 demonstrates, administering a-2 adrenergic receptor agonists leads to constriction of the pre-capillary/ierminal arteriole (i.e. smaller blood vessel) (on the left side of FIG. 1) and constriction of the venule (on the right side of FIG. 2). Ischemia is
decreased, as compared to stimulating a-1 adrenergic receptors, because the arteriole is open and some oxygen is available to surrounding tissues by means of the through-flow vessels that connect the arterioles and the venules.
[0119] FIG. 3 is a visual representation of three different shades of whiteness. The human eye has a limit to its ability to discriminate shades of whiteness change. The central square is set to RGB (255 255 255). The RGB color model is an additive color model in which red, green, and blue light are added together in various ways to reproduce a broad array of colors. A color in the RGB color model is described by indicating how much of each of the red, green, and blue is included. The color is expressed as an RGB triplet (rgb), each component of which can vary from zero to a defined maximum value. If all the components are at zero, the result is black; if all are at maximum, the result is the fully saturated white, RGB (255 255 255) represents the fully saturated white.
[0120] In the right square, the whiteness has been reduced by 5, based on a 1 to 100 blackness scale, where the background is 100. On the square to the left, the whiteness has been reduced by 15. The shade differential resulting from reduction by 5 is just above the threshold increment of difference in whitening detectable by most humans with normal healthy eyes.
[0121] FIG. 4a is a photograph of an eye of a patient with hyperemia. Hyperemia (dilation of vessels of the conjunctiva, and less frequently underlying episclera and/or sclera) masks the whiteness of the sclera and is a common cause of increased eye redness and reduced eye whiteness. It results in the classic "red eye". However, on a more fundamental physiological level, whiteness of the sclera varies from individual to individual, even in the absence of pathology. This is demonstrated by FIGs. 4b-4d which are photographs of eyes of healthy individuals.
[0122] FIG. 5 illustrates the new scale according to the present invention which allows one to quantify sclera color beyond removal of hyperemia
[0123] FiGs 6-14B are explained in the Examples.
[0124] The following Examples are provided solely for illustrative purposes and are not meant to limit the invention in any way.
Examples
Example 1 -Effect of Brimonidine on Increasing Whiteness of an Eye
[0125] A patient with glaucoma who was receiving Lumigan® (bimatoprost ophthalmic solution 0.03%; a trademark of AUergan, Inc.), treatment, was administered 0,025% brimonidine to reduce redness and increase whiteness of an eye. FIG. 9A is a photograph of the eye prior to administration of 0.025% brimonidine. FIG. 9B is a photograph of the same eye after administration of 0.025% brimonidine.
[0126] This Example demonstrates that 0.025% brimonidine resulted in significant reduction of redness and increase of whiteness of an eye.
Example 2~Effect of Brimonidine on Increasing Whiteness of an Eye
[0127] A child patient was administered 0,025% brimonidine to reduce redness and increase whiteness of an eye. FIG. 10 is a photograph of the eye after administration of 0.025% brimonidine.
[0128] This Example demonstrates that 0.025% brimonidine resulted in significant reduction of redness and increase of whiteness of an eye.
Example 3-Effect of Brimonidine on Increasing Whiteness of an Eye and Nasal
Decongestion
[0129] Eight (8) human subjects were administered 0.025% brimonidine. The subjects were administered with the drug in one eye and then asked to assess themselves in the mirror to see if they perceived a difference in conjunctival hyperemia between eyes. The assessments were
made 5 minutes after the administration and 4 hours after the administration. After the four hours assessment, the drug was re-administered.
[0130] The results of the experiment are as follows. At the initial 5 mm assessment, eight of eight subjects reported reduced hyperemia and increased whiteness in the eye to which brimonidine was administered, At the four hour assessment, eight of eight subjects reported reduced hyperemia and increased whiteness in the eye to which brimonidine was administered. Aiso, at the four hour assessment, six of eight subjects reported reduced nasal congestion in. the nostril on the same side as the eye into which the drug was administered. {0131] Photographs of the subjects' eyes were taken 5 minutes after the re-administration of brimonidine at 4 hours after the initial administration.
[0132] FIG. 8 is a photograph of subject #1, the drug was administered into the left eye; the right eye is control;
[0133] FIG. 9 is a photograph of subject #2, the drug was administered into both eyes;
[0134] FIG. 10 is a photograph of subject #3, the drug was administered into the right eye; the left eye is control;
[0135] FIG. 1 1 A is a photograph of subject #4, the photograph is the baseline and was taken prior to administration of the drug;
[0136] FIG. 1 IB is a photograph of subject #4, the drug was administered into the right eye; the left eye is control; and
[0137] FIG. 12 is photograph of subject #5, the drug was administered into the righ eye; the left eye is control.
[0138] As this Example demonstrates, administration of low dose brimonidine resulted in a significant reduction of redness and increase of whiteness of eyes. In addition, in se veral subjects, administration of brimonidine into the eye resulted in reducing nasal congestion in the nostril on the same side as the eye into which the drug was administered.
Example 4-Effeet ofBrimonidine on Increasing of Cosmetic Whiteness of an Eye [0139] A 40-year-old woman with healthy eyes was administered 1 gtt (dro per minute) of 0.025% brirrsomdine into the right eye for three minutes. FIG. 13 is a photograph of both eyes of the woman before the drug was administered. FIG. 14A is a ciose-up photograph of the right eye and FIG. 14B is a close-up photograph of the left eye.
[01 0] This Example demonstrates that the right eye was noticeably cosmetically whitened after administration of 0.025% brimoriidme.
Exampl 5-Effect of selective a-2 adrenergic receptor agonists on Whiteness of an
Eye
Table 1. Redness reduction and whitening effects of selective a-2 adrenergic receptor agonists
[0141] "TBD" denotes to be determined.
[0142] Redness reduction is on a scale from 0.00 to 4.00 with 0.00 denoting the greatest redness reduction and 4.00 denoting no redness reduction.
[0143] Whitening is on a scale from 0.00 to 4.00 with 0.00 denoting pearly white, glistening color and 4.00 denoting no whitening effect.
[0144] As seen in Table 1, brimonidine, dexmedetomidine and guanfacine are all highly effective at reducing both general eye redness and eye redness induced by drug
administration. The comparable baseline redness (i.e. before application of an a-2 agonist)
for general is 2+ on a 4.0 scale and drug induced redness score is 3+ on a 4.0 scale with 0.0 denoting no redness and 4.0 denoting the most redness.
{0145] Also seen in Table 1 is the general ineffectiveness of brimonidine at further whitening eyes beyond their usual color after redness inducing drug administration. Whereas, dexmedetomidine is generally ineffective at further whitening eyes beyond their usual color with or without redness induced by drug administration. Surprisingly, guanfacine is highly effective at further wh itening eyes beyond their usual color regardless of whether redness was induced by drug administration.
Claims
1 . A method of increasing whiteness of an eye comprising administering to a subject in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 foid or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein said selective a-2 adrenergic receptor agonist has a binding affinity of 500 fold or greater for a-2 over a-1 adrenergic receptor.
3. The method of claim 1, wherein said selective a-2 adrenergic receptor agonist is selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+)~(S)-4-[ 1 -^S-dimethyl-pheny -ethyl]-!^- dihydro-imidazole-2-thione, i -[(imida/.oltdin-2-yl)iminojindazole, and mixtures of these compounds.
4. The method of claim 1 , wherein said a-2 adrenergic receptor agonist is present at a concentration from about 0.001 % to about 0.06% weight by volume.
5. The method of claim 1 , wherein said a-2 adrenergic receptor agonist is
dexmedetomidine at. a concentration from about 0,01% to about 0.060% weight by volume.
6. The method of claim 1, wherein said a-2 adrenergic receptor agonist is guanfacine at a concentration from about 0.01 % to about 0.028% weight by volume.
7. The method of claim 1, wherein said a-2 adrenergic receptor agonist is
fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
8. The method of claim 1, further comprising from about 0.005% to 0.01% weight by volume of calcium chloride.
9. A method of reducing redness of .an eye comprising administering to a subject, in need thereof a composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
10. The method of claim 9, wherein said selective ~2 adrenergic receptor agonist has a binding affinity of 500 fold or greater for a-2 over a-1 adrenergic receptor.
1 1. The method of claim 9, wherein said selective a-2 adrenergic receptor agonist is selected from the group consisting of brinionidine, alpha methyl dopa, guanfacine, f dolrnidine, dexmedetomidine, (+)-(S)-4-[l-(2,3-dimethyl-phenyi)-ethyl]-l53- dihydro-imidazole-2~thione, l-[(imidazolidin-2-yi)imino]indazoIe, and mixtures of these compounds.
12. The method of claim 9, wherein said a-2 adrenergic receptor agonist is present at a concentration from about 0.001% to about 0.06% weight by volume.
13. The method of claim 9, wherein said ~2 adrenergic receptor agonist is
dexmedetomidine at a concentration from about 0.01 % to about 0.060% weight by volume.
14. The method of claim 9, wherein said a-2 adrenergic receptor agonist is guanfacine at a concentration from about 0.01% to about. 0.038% weight by volume.
15. The method of claim 9, wherein said a-2 adrenergic receptor agonist is
fadolmidine at a concentration from about 0.01% to about 0.025% weight by volume.
16. The method of claim 9, further comprising from about 0.005% to 0.01% weight by volume of calcium chloride.
17. A method of reducing redness of an eye while simultaneously increasing
whiteness of the eye comprising administering to a subject in need thereof a
composition comprising a selective a-2 adrenergic receptor agonist having a binding affinity of 300 fold or greater for a-2 over a-1 adrenergic receptors, or a pharmaceutically acceptable salt thereof.
18. The method of claim 37, wherein said selective a-2 adrenergic receptor agonist has a binding affinity of 500 fold or greater for a-2 over a-1 adrenergic receptor.
1 . The method of claim 17, wherein said selective a-2 adrenergic receptor agonist is selected from the group consisting of brimonidine, alpha methyl dopa, guanfacine, fadolmidine, dexmedetomidine, (+)-(S)-4-{ 1 -{2,3-dimethyi-phenyl)~ethyl]- 1 ,3- dihydro-imidazoie-2-thione, l -[(imidazolidin-2-yl)imino]mdazo!e, and mixtures of these compounds.
20. The method of claim 17, wherein said a~2 adrenergic receptor agonist is present at a concentration from about 0.001% to about 0.06% weight by volume.
21. The method of claim ! , wherein the composition further comprises a cyclodextrin.
22. The method of claim 21 wherein the cyclodextrin is 2 hydroxypropyl beta
cyclodextrin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/044,933 US20140038974A1 (en) | 2009-12-17 | 2013-10-03 | Compositions and Methods for Eye Whitening |
US14/044,933 | 2013-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015050670A1 true WO2015050670A1 (en) | 2015-04-09 |
Family
ID=52779027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/054288 WO2015050670A1 (en) | 2013-10-03 | 2014-09-05 | Compositions and mehthods for eye whitening |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015050670A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222525A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine compositions and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160214A1 (en) * | 2009-12-17 | 2011-06-30 | Gerald Horn | Compositions and methods for eye whitening |
US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
-
2014
- 2014-09-05 WO PCT/US2014/054288 patent/WO2015050670A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160214A1 (en) * | 2009-12-17 | 2011-06-30 | Gerald Horn | Compositions and methods for eye whitening |
US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222525A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine compositions and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9259425B2 (en) | Compositions and methods for eye whitening | |
US11833245B2 (en) | Vasoconstriction compositions and methods of use | |
EP2696874A2 (en) | Compositions and methods for the treatment of nasal conditions | |
JP2005523316A (en) | Combination of brimonidine and timolol for topical ophthalmology | |
US8987270B2 (en) | Formulations of selective alpha-2 agonists and methods of use thereof | |
JP2021046394A5 (en) | ||
US20110257188A1 (en) | Compositions and methods for the treatment of nasal conditions | |
US20110152271A1 (en) | Compositions and methods for ophthalmic delivery of nasal decongestants | |
JP6612774B2 (en) | Pharmacotherapy to prevent or treat glaucoma | |
US20140038974A1 (en) | Compositions and Methods for Eye Whitening | |
WO2015050670A1 (en) | Compositions and mehthods for eye whitening | |
US20180369240A1 (en) | Preferential Vasoconstriction Compositions and Methods of Use | |
US20150119401A1 (en) | Compositions and Methods for the Treatment of Nasal Conditions | |
WO2015031183A1 (en) | Compositions and methods for the treatment of nasal conditions | |
US8952011B2 (en) | Compositions and methods for the treatment of nasal conditions | |
SODA et al. | The effect of brimonidine on intraocular pressure via the central nervous system in the conscious pigmented rabbit | |
WO2012060860A1 (en) | Treatment of ocular and cerebral ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14850620 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14850620 Country of ref document: EP Kind code of ref document: A1 |